IP Library Granted Patent US 8,796,021
Granted Patent B2
US 8,796,021 · App. 12/528,212 · Granted Aug 5, 2014

Blastomere culture to produce mammalian embryonic stem cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,796,021
App. No.
12/528,212
Granted
Aug 5, 2014
Kind
B2
Abstract

The present invention relates generally to the field of somatic cell nuclear transfer (SCNT) and to the creation of cloned animals and cells. The disclosure relates to a method of cloning a mammal, obtaining pluripotent cells such as embryonic stem cells, or for reprogramming a mammalian cell using an oocyte and a fertilized embryo.

Claims (10)

1. A method of producing an mammalian embryonic stem (ES) cell, comprising

(a) culturing a mammalian blastomere for 12 to 18 hours;

(b) transferring the blastomere to blastocyst medium further comprising laminin and seeded with fibroblasts; and

(c) culturing the blastomere of (b) until ES cells are produced.

2. The method of claim 1 , wherein the fibroblasts are mitotically inactivated, wherein step (c) comprises culturing in conditions that reduce embryonic vesicle formation, wherein the blastocyst medium comprises 2.5 μg/ml of laminin, and wherein step (c) comprises culturing in blastocyst medium seeded with fibroblasts for 5 days.

3. The method of claim 1 , wherein step (c) further comprises culturing until the blastomeres form cell clumps of about 20 cells and transferring the cell clumps to medium seeded with ES cells that express a marker or are labeled.

4. The method of claim 1 , wherein step (a) comprises culturing said blastomere with a mammalian parental embryo from which said blastomere was obtained.

5. The method of claim 1 , wherein said blastomere is human.

6. The method of claim 1 , wherein step (b) comprises culturing said blastomere in indirect contact with pluripotent cells.

7. The method of claim 1 , wherein said fibroblasts are mouse embryonic fibroblasts.

Assignments (5)
CHANGE OF NAME Recorded Jul 27, 2016
From: OCATA THERAPEUTICS, INC.
To: ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
Reel/Frame 039493/0166 →
CHANGE OF NAME Recorded Jan 24, 2016
From: ADVANCED CELL TECHNOLOGY, INC.
To: OCATA THERAPEUTICS, INC.
Reel/Frame 037578/0698 →
RELEASE OF SECURITY INTEREST Recorded Nov 24, 2014
From: CAMOFI MASTER LDC; CAMHZN MASTER LDC
To: ADVANCED CELL TECHNOLOGY, INC.; MYTOGEN, INC.
Reel/Frame 034421/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2014
From: CHUNG, YOUNG; LANZA, ROBERT
To: ADVANCED CELL TECHNOLOGY, INC.
Reel/Frame 034112/0637 →
SECURITY AGREEMENT Recorded Jan 25, 2013
From: ADVANCED CELL TECHNOLOGY, INC.; MYTOGEN, INC.
To: CAMOFI MASTER LDC; CAMHZN MASTER LDC
Reel/Frame 029698/0001 →